Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

Journal of controlled release : official journal of the Controlled Release Society - 1 Apr 2022

Cho Young Seok, Kim Gui Chul, Lee Hye Min, Kim Byoungmo, Kim Ha Rin, Chung Seung Woo, Chang Hyo Won, Ko Yoon Gun, Lee Yoon Se, Kim Seong Who, Byun Youngro, Kim Sang Yoon

Abstract excerpt

Despite recent breakthroughs in the development of direct KRAS inhibitors and modulators, no drugs targeting pan-KRAS mutant cancers are clinically available. Here, we report a novel strategy to treat pan-KRAS cancers using a caspase-3 cleavable peptide-drug conjugate that exploits enhanced albumin metabolism in KRAS altered cancers to deliver a cytotoxic agent that can induce a widespread bystander killing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Neoplasms

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 35202743
DOI: 10.1016/j.jconrel.2022.02.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.PMID 35202743Read ↗

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read ↗

Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment.Semantic proximity Read ↗

Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.Semantic proximity Read ↗

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.Semantic proximity Read ↗

Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Semantic proximity Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

U1 Adaptors Suppress the KRAS-MYC Oncogenic Axis in Human Pancreatic Cancer Xenografts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.